What is the impact of new safety information on a clinical trial?

• A. It has no effect on participant safety or trial conduct.
• B. It only affects regulatory submissions.
• C. It can affect participant safety, their willingness to continue in the trial, or the conduct of the trial.
• D. It requires immediate halting of the trial in all cases.

Answer: (C)

New safety information triggers a reassessment of risk versus benefit in a trial. When new safety insights emerge—such as unexpected serious adverse events, new risk signals from the data, or external safety data—the sponsor and investigators must evaluate how the new information affects participant safety and the trial’s continuation. This can influence whether participants are willing to continue and can change how the trial is conducted: increasing safety monitoring, updating the protocol, adjusting inclusion criteria, modifying the informed consent to reflect new risks, and communicating findings to ethics committees and regulators. It may also lead to actions like pausing dosing or stopping the trial if the risks outweigh the benefits. Halting the trial is not automatic in every case; the response depends on the level of risk and the overall risk-benefit assessment.